



**CCM DUOPHARMA BIOTECH BERHAD (524271-W)**  
 (Incorporated in Malaysia)  
**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME**  
**FOR THE PERIOD ENDED 30 JUNE 2017**

	INDIVIDUAL PERIOD		CUMULATIVE PERIOD	
	CURRENT YEAR QUARTER 6/30/2017 RM'000	PRECEDING YEAR CORRESPONDING QUARTER 30/06/2016 RM'000	CURRENT YEAR TO DATE 6/30/2017 RM'000	PRECEDING YEAR CORRESPONDING PERIOD 30/06/2016 RM'000
Revenue	117,049	79,135	240,355	158,605
Cost of Sales	(67,394)	(43,283)	(146,098)	(86,496)
<b>Gross Profit</b>	<b>49,655</b>	<b>35,852</b>	<b>94,257</b>	<b>72,109</b>
Other operating income	35	97	136	225
Distribution costs	(22,187)	(16,107)	(39,952)	(31,554)
Administration expenses	(13,640)	(11,626)	(27,291)	(21,876)
Other operating expenses	(470)	(76)	(1,037)	(573)
<b>Profit from operations</b>	<b>13,393</b>	<b>8,140</b>	<b>26,113</b>	<b>18,331</b>
Finance income	588	949	1,303	2,171
Finance costs	(1,339)	(1,366)	(2,652)	(2,838)
<b>Profit before taxation</b>	<b>12,642</b>	<b>7,723</b>	<b>24,764</b>	<b>17,664</b>
Taxation	(3,001)	(3,782)	(5,559)	(5,895)
<b>Profit after tax for the period</b>	<b>9,641</b>	<b>3,941</b>	<b>19,205</b>	<b>11,769</b>
<b>Other comprehensive income</b>				
Foreign currency translation differences for foreign operations	12	562	12	577
<b>Total other comprehensive income for the period</b>	<b>9,653</b>	<b>4,503</b>	<b>19,217</b>	<b>12,346</b>
<b>Profit attributable to:</b>				
Shareholders of the Company	9,653	4,503	19,217	12,346
Minority interest	-	-	-	-
	<b>9,653</b>	<b>4,503</b>	<b>19,217</b>	<b>12,346</b>
<b>Total comprehensive income attributable to:</b>				
Shareholders of the Company	9,653	4,503	19,217	12,346
Minority interest	-	-	-	-
	<b>9,653</b>	<b>4,503</b>	<b>19,217</b>	<b>12,346</b>
Earnings per share (sen)				
Basic (based on weighted average)	3.46	1.41	6.88	4.22
Diluted (based on weighted average)	3.46	1.41	6.88	4.22

- The Condensed Consolidated Income Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2016 and the accompanying explanatory notes attached to the interim financial statements.



**CCM DUOPHARMA BIOTECH BERHAD (524271-W)**  
(Incorporated in Malaysia)  
**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION**  
**AS AT 30 JUNE 2017**

	AS AT 30/6/2017 RM'000	AS AT 31/12/2016 RM'000
<b>ASSETS</b>		
Property, Plant and Equipment	289,205	276,241
Intangible assets	15,135	12,727
Deferred Tax Assets	6,575	6,313
<b>Total non-current assets</b>	<b>310,915</b>	<b>295,281</b>
Inventories	146,761	139,101
Trade & Other Receivables	133,020	94,378
Amount Due From Related Company	4,418	6,653
Current Tax Assets	10,010	10,236
Cash & Cash Equivalents	82,917	114,814
	377,126	365,182
Asset Held For Sale	1,000	1,000
<b>Total current assets</b>	<b>378,126</b>	<b>366,182</b>
<b>Total Assets</b>	<b>689,041</b>	<b>661,463</b>
<b>EQUITY</b>		
Share Capital	139,478	139,478
Reserves	193,784	193,772
Retained earnings	129,313	121,266
<b>Total Equity</b>	<b>462,575</b>	<b>454,516</b>
<b>LIABILITIES</b>		
Deferred Tax Liability	10,024	11,993
Borrowings	81,798	91,798
<b>Total non-current liabilities</b>	<b>91,822</b>	<b>103,791</b>
Trade & Other Payables	77,450	58,775
Amount due to related company	24,431	22,883
Borrowings	32,763	21,498
Taxation	-	-
<b>Total current liabilities</b>	<b>134,644</b>	<b>103,156</b>
<b>Total Liabilities</b>	<b>226,466</b>	<b>206,947</b>
<b>Total Equity &amp; Liabilities</b>	<b>689,041</b>	<b>661,463</b>
	-	-
<b>Net assets per share (RM)</b>	<b>1.66</b>	<b>1.63</b>



CCM DUOPHARMA BIOTECH BERHAD (524271-W)  
(Incorporated in Malaysia)  
**UNAUDITED CONDENSED CONSOLIDATED CASH FLOW STATEMENT**  
FOR THE PERIOD ENDED 30 JUNE 2017

	30 June 2017	30 June 2016
	RM '000	RM '000
<b>Cash flows from operating activities</b>		
Profit before taxation	24,764	17,664
Adjustments for:		
Depreciation of property, plant and equipment	11,304	11,119
Interest income	1,303	2,171
Finance costs	(2,652)	(2,838)
Negative goodwill	-	-
<i>Operating profit before changes in working capital</i>	34,719	28,116
Change in inventories	(7,660)	(17,959)
Change in receivables, deposits and prepayments	(34,855)	(3,259)
Change in payables and accruals	15,413	12,628
<i>Cash generated from operations</i>	7,617	19,526
Finance costs paid	2,652	2,838
Interest income	(1,303)	(2,171)
Income tax paid	(6,702)	(4,556)
Net cash generated from operating activities	2,264	15,637
<b>Cash flows from investing activities</b>		
Acquisition of property, plant and equipment	(24,268)	(11,230)
Acquisition of subsidiary, net of cash and cash equivalents acquired	-	-
Proceed from issuance of shares	-	-
Net cash used in investing activities	(24,268)	(11,230)
<b>Cash flows from financing activities</b>		
Drawdown of borrowings	16,265	-
Repayment of borrowings	(15,000)	(10,000)
Dividends paid to shareholders of the Company	(11,158)	(15,343)
Net cash used in financing activities	(9,893)	(25,343)
Exchange differences on translation of financial statements of foreign operations		
Net decrease in cash and cash equivalents	(31,897)	(20,936)
Cash and cash equivalents at 1 January	114,814	143,510
Cash and cash equivalents as at 30 June	82,917	122,574
(i) Cash and cash equivalents comprise:		
	<b>RM '000</b>	<b>RM '000</b>
Cash and bank balances	28,910	29,589
Deposits placed with licensed financial institutions	54,007	92,985
	82,917	122,574

(The Condensed Consolidated Cash Flow Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2016 and the accompanying explanatory notes attached to the interim financial statements.)